A Phase 3, Double-Blind, Placebo-controlled study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD

Administered By

Awarded By

Contributors

Start/End

  • August 22, 2016 - August 21, 2021